|Description||Aliskiren hemifumarate appears to bind to both the hydrophobic S1/S3-binding pocket and to a large, distinct subpocket that extends from the S3-binding site towards the hydrophobic core of renin. Oral bioavailability of Aliskiren hemifumarate is 2.4% in rats, 16% in marmosets and about 2.5% in humans. Aliskiren hemifumarate (< 10 mg/kg, oral) inhibits plasma renin activity and lowers blood pressure in sodium-depleted marmosets.Once-daily oral treatment with Aliskiren hemifumarate lowers blood pressure effectively, with a safety and tolerability profile, in patients with mild-to-moderate hypertension.|
|Synonyms||CGP 60536; CGP60536B; Rasilez; SPP 100; Tekturna|
VTP-27999 Hcl is an alkyl amine Renin inhibitor; VTP-27999 is useful for Hypertension and End-Organ Diseases.
CI 992 is a renin inhibitor originated by Pfizer. Preclinical trials for Hypertension in USA was discontinued in 1994.
Remikiren is a renin inhibitor originated by Roche in 1996. But clinical trials for the treatment of Heart failure and Hypertension was discontinued.
PD 132002 is a renin inhibitor originated by Pfizer. In Dec 2001, clinical trials for Hypertension in USA was discontinued.
Aliskiren hemifumarate appears to bind to both the hydrophobic S1/S3-binding pocket and to a large, distinct subpocket that extends from the S3-binding site tow...
CP 84364 is an active metabolite of CP-80794 which is a Renin inhibitor.
ACT 178882 is a novel Renin inhibitor (IC50= 1.4 nM).
VTP-27999 2,2,2-trifluoroacetate is an alkyl amine Renin inhibitor, useful for Hypertension and End-Organ Diseases.
VTP-27999 is an alkyl amine Renin inhibitor. It is useful for Hypertension and End-Organ Diseases.
Aliskiren hemifumarate is an orally bioactive renin inhibitor (human IC50 = 0.6 nM; rat IC50 = 80 nM) appearing to bind to both the hydrophobic S1/S3-binding po...
PD 125967 is a renin inhibitor which may be useful for treatment of essential hypertension.
This active molecular is a Renin inhibitor that applicated in treatment of essential hypertension.